Lizza Hendriks
@HendriksLizza
Followers
967
Following
1K
Statuses
400
Pulmonologist - thoracic oncology, esp brain metastases @MaastrichtUMC @GROW_UM- member @DeJongeAkademie - @myESMO #LungCancer faculty - @EORTC - Views my own
Maastricht, Nederland
Joined March 2019
RT @DrJNaidoo: De-Escalation Strategies With ICIs in NSCLC: Do We Already Have Enough Evidence? @JCO_ASCO Pleased to contribute to this g…
0
20
0
RT @myESMO: 📣 Just updated: ESMO Oncogene-addicted mNSCLC Living Guideline v1.2 🧬 Find new recommendations with links to ESMO-MCBS scores,…
0
12
0
@OncLive @peters_solange @CHUVLausanne @myESMO @IASLC @Women4Oncology “You will get back way more than you had been giving by being collaborative...the whole environment will be modified around you in a positive manner👏👏
0
0
4
@santhoshak23220 @oncodaily @myESMO My full ESMO Asia preceptorship ppt from beginning of dec is available online for those interested!
0
0
4
Some patients with oligometastatic NSCLC do benefit from radical therapy, but the majority doesn’t and has only a risk of treatment related tox. Biomarkers urgently needed. Read our review in @JTOonline thanks to all collaborators
0
12
32
RT @oncodaily: Our @EORTC survey on resectability of stage III NSCLC – @Ilias_Houda (@amsterdamumc) @BenjaminBesseMD @HendriksLizza https:…
0
1
0
RT @TAMedOncol: Patients with NSCLC on TKIs report few toxicities but sometimes miss symptoms as treatment-related. TDM-guided dosing is we…
0
2
0
Big challenge to find biomarkers and improve therapy in SCLC. Collaboration is key!
The sclc revolution with immunotherapy and TCEs but molecular biology still complicated to select therapies...very nice presentation by @HendriksLizza during this Lung preceptorship by @myESMO
0
7
22
RT @dplanchard: Important messages for our patients (e.g. ALK, ROS1…) who will be taking the treatments for extended periods. Thank you @He…
0
6
0
RT @dplanchard: Very nice session to discuss clinical cases and move on to the metastatic stage. @myESMO @HendriksLizza @BenjaminBesseMD @A…
0
4
0
RT @_knaw: Vandaag in @volkskrant @ADnl: Kabinet, maak niet kapot wat ons land zo succesvol maakt. Stop met de onverantwoorde #bezuiniging…
0
145
0
@dplanchard @peters_solange @myESMO On my way! Looking forward to the preceptorship and catching up with all of you @myESMO
0
0
4
RT @MIgnatiadis: Patient centric academic research is dying in Europe due to bureaucratic EU clinical trials regulations! Check this letter…
0
8
0
RT @myESMO: 👉 There is still time to join this discussion on #LeptomeningealMetastasis. Get your questions answered to implement the #ESMOG…
0
11
0
Fully agree! You need people who challenge and support you to grow
Superb article on the secret sauce of team science, in @NatureBiotech: It takes two to think ‘Morale thrives on the encouragement we get from the feedback of someone who understands our work & it’s motivations’ Great read
0
0
12
RT @DiseasePrimers: Our NEW Primer on Non-small-cell lung cancer is live today! By @HendriksLizza @JordiRemon @finn_corinne @marinagarassin…
0
7
0
There is an ongoing debate about PCI in SCLC, as there is a risk of neurocognitive decline, opposed to the benefit of reduced risk of brain mets. What if we could predict risk of neurotox & personalize PCI? Our first hypothesis generating data just out!
1
11
27
Honored to be part in this project, with an up-to-date broad overview on NSCLC, from risk factors to diagnosis, therapy and QoL
🔥 Publised online today @Nature Reviews Disease Primers - NSCLC - wonderful collaboration with outstanding colleagues led by @MartinReck2
@JordiRemon @HendriksLizza @danieltanmd @GarassinoMarina
@TheChristieNHS @MCRCnews
@IASLC @EORTC @myESMO
0
3
15
RT @high5md: #ESMO24 recap is here! 📺 Important data, expert opinions – all available now on #high5oncologyTV. Free & on demand! https://t.…
0
8
0